evans blue has been researched along with glyceraldehyde 3-phosphate in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Date, I; Liu, K; Maruo, T; Mori, S; Nishibori, M; Ohtsuka, A; Okuma, Y; Otani, N; Shima, K; Takahashi, HK; Tomura, S; Wake, H; Yamamoto, H; Yamamoto, Y; Yoshino, T; Zhang, J | 1 |
1 other study(ies) available for evans blue and glyceraldehyde 3-phosphate
Article | Year |
---|---|
Anti-high mobility group box-1 antibody therapy for traumatic brain injury.
Topics: Analysis of Variance; Animals; Blood-Brain Barrier; Brain Edema; Brain Injuries; Cell Death; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Evans Blue; Functional Laterality; Gene Expression Regulation; Glycation End Products, Advanced; Glyceraldehyde 3-Phosphate; HMGB1 Protein; Hypoxia-Inducible Factor 1; Immunoglobulin G; Magnetic Resonance Imaging; Male; Mice; Mice, Knockout; Microscopy, Electron, Transmission; Microtubule-Associated Proteins; Motor Activity; Neurons; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Wistar; Rotarod Performance Test; Toll-Like Receptor 2; Toll-Like Receptor 4 | 2012 |